How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,172 results for

Headache in Pregnancy

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

5021. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). (Abstract)

contraindications to IUDs.Incidence of complaints, conditions, and rates of specific termination for each IUD.Subjects recorded menstrual events, and clinical staff registered all complaints and conditions found on examination at four first-year clinic visits and at semiannual visits thereafter. Difference in rates were analyzed by chi 2 statistics.Annual pregnancy rates for each IUD averaged 0.2/100 women whereas upper genital tract infection occurred at rates of 0.6 to 0.7 per 100 years of use (...) . The levonorgestrel-releasing IUD significantly decreased bleeding and spotting days in comparison with historical data for noncontraceptors and with the copper-medicated IUD. Dysmenorrhea, vaginitis, and myoma in women with the levonorgestrel IUD were markedly decreased in comparison with the experience of copper IUD users. Significantly higher rates of amenorrhea, delayed ovarian follicular atresia, skin and hair conditions, and headache were observed with the steroid IUD than with the copper-releasing IUD

1994 Fertility and sterility Controlled trial quality: uncertain

5022. Subcutaneous goserelin versus intranasal buserelin for pituitary down-regulation in patients undergoing IVF: a randomized comparative study. (Abstract)

in the goserelin group was 6.7 +/- 5.0 versus 6.3 +/- 4.9 in the buserelin group. There were 11 pregnancies after the use of goserelin (22.4%) and 12 pregnancies in those given buserelin (24.0%). The number of HMG ampoules needed for follicular maturation was higher in the goserelin group (27.9 +/- 7.8) than in the buserelin group (24.6 +/- 7.8, P < 0.05). The patients given buserelin suffered significantly more from tiredness, depression, headache and abdominal pain than those receiving goserelin, whereas

1993 Human reproduction (Oxford, England) Controlled trial quality: uncertain

5023. Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30 years of age. (Abstract)

cycles. The two groups were comparable in terms of demographic and gynaecologic characteristics at baseline. However, the menstrual flow length was slightly longer in the GES/EE group before the start of the treatment. The mean age (+/- SD) was 35 +/- 4 years in the GES/EE group and 35 +/- 5 years in the DES/EE group. The subjects in the GES/EE group contributed data for a total of 2800 cycles and those in the DES/EE group, data for 2796 cycles. There were no pregnancies on medication with either (...) in terms of primary reasons for withdrawal. The most frequently reported complaints that led to discontinuation in both groups were headache, nausea and metrorrhagia. Breast tenderness led to the discontinuation of 1 subject in the GES/EE group and 3 in the DES/EE group. These results show excellent cycle control, efficacy and very low rate of side effects with both GES/EE and DES/EE. These low-dose oral contraceptives could be well suited to healthy nonsmoking women requiring contraception up

1994 Contraception Controlled trial quality: uncertain

5024. A multicenter comparative trial of triphasic and monophasic, low-dose combined oral contraceptives. (Abstract)

, subjects were randomly allocated to one of the two OCs. Follow-up visits were scheduled at 1, 4, 8 and 12 months after admission. There were two accidental pregnancies attributed to user failure reported during the study period; one in the triphasic group and one in the monophasic group. Adverse experiences were mainly minor with headaches and dizziness being the most common complaints; frequency of reports was similar in both groups. Cycle control was good in both groups with women in the triphasic

1993 Contraception Controlled trial quality: uncertain

5025. Hemorrhagic fever with renal syndrome presenting with intrauterine fetal death. A case report. (Abstract)

day before being referred to our department with the additional symptoms of headache, lumbodynia and orbital pain. On examination, she had a normal body temperature, flushing of the face, conjunctive congestion, pharyngeal congestion, bulbar conjunctive edema, severe jaundice, petechiae and ecchymosis at sites of venipuncture, deranged liver and renal function tests, heavy proteinuria and hematuria, and coagulation disturbance. The diagnosis of HFRS complicating pregnancy was made on account (...) Hemorrhagic fever with renal syndrome presenting with intrauterine fetal death. A case report. Hantavirus infection in pregnancy is rare. Only 2 cases of hantavirus pulmonary syndrome have been reported in the English-language literature. We report a case of hemorrhagic fever with renal syndrome (HFRS) complicating pregnancy to alert clinicians to this rare possibility.A 29-year-old woman had experienced persistent, high fever for 6 days, no fetal movement for 2 days and frequent vomiting for 1

2003 Journal of Reproductive Medicine

5026. Arnold-Chiari malformation in a pregnant woman. (Abstract)

Arnold-Chiari malformation in a pregnant woman. The Arnold-Chiari malformation type I is characterized by the prolapse of the cerebellar tonsils below the foramen magnum. There is a lack of literature on the management of a pregnancy in a woman affected by an Arnold-Chiari malformation.A young primipara with severe headaches underwent an elective primary cesarean delivery under general anesthesia successfully. Five years earlier, she had undergone neurosurgical resection for filum terminale (...) syndrome shortly after her first pregnancy (term vaginal delivery) and decompression of a type I Arnold-Chiari malformation 4 months later.Careful selection of anesthetic technique for the delivery of a woman with an Arnold-Chiari malformation is of paramount importance.

2003 Obstetrics and Gynecology

5027. Postpartum seizure prophylaxis: using maternal clinical parameters to guide therapy. (Abstract)

Postpartum seizure prophylaxis: using maternal clinical parameters to guide therapy. To use individual patient clinical parameters to signal cessation of postpartum magnesium sulfate seizure prophylaxis for the spectrum of pregnancy-related hypertensive disorders.This was a prospective study using clinical symptoms (absence of headache, visual changes, epigastric pain) and signs (sustained blood pressure less than 150/100 without need for acute antihypertensive therapy, spontaneous diuresis (...) patients (7.6%) required reinstitution of magnesium therapy for 24 hours because of exacerbation of blood pressure (sustained blood pressure more than 160/110) associated with headache or visual changes.Clinical criteria, when compared with arbitrary protocols, can be used successfully to shorten the duration of postpartum magnesium sulfate administration for seizure prophylaxis in patients with pregnancy-related hypertensive disorders.

2003 Obstetrics and Gynecology

5028. A randomized, double-blind study of two combined and two progestogen-only oral contraceptives. (Abstract)

, and at two years pregnancy rates and discontinuation rates for bleeding disturbances, were significantly lower in the EE/LNG preparation. The groups receiving the MES/NET, LNG and NET had similar pregnancy rates, discontinuation rates for all medical reasons and all bleeding disturbances. There were two ectopic pregnancies among the 22 pregnancies in the progestogen-only groups. Discontinuation because of headache, dizziness and other central nervous system symptoms were significantly more common

1982 Contraception Controlled trial quality: uncertain

5029. Posterior reversible encephalopathy syndrome (PRES) in critically ill obstetric patients. (Abstract)

of them presented cortical blindness and headache, too. True status epilepticus (SE) occurred in two cases. In all patients MRI showed the typical feature of gray-white matter edema, mainly localized to the temporo-parieto-occipital areas.Normalization of high blood pressure (BP) and treatment of seizures. Two patients with SE and severe impairment of consciousness were treated with an intravenous valproate (ivVPA) bolus followed by continuous infusion.In three cases, neurological and MRI (...) abnormalities completely resolved in about a week. Another patient died due to subarachnoid hemorrhage.Posterior reversible encephalopathy syndrome is a well described clinical and neuroradiological syndrome characterized by headache, altered mental status, cortical blindness and seizures, and a diagnostic MRI picture; usually reversible, PRES can sometimes result in death or in irreversible neurological deficits, thus requiring early diagnosis and prompt treatment. PRES can have various etiologies

2003 Intensive Care Medicine

5030. Women's Use of Alternative Medicine: A Multiethnic Study

conditions within the last year: pregnancy related symptoms menopausal related symptoms headaches back pain osteoporosis cancer high blood pressure high cholesterol heart disease joint pain/arthritis insomnia uterine fibroids urinary tract infection vaginal tract infection medically diagnosed depression menstrual symptoms Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact (...) Depression Headaches Study Design Go to Layout table for study information Study Type : Observational Enrollment : 3200 participants Allocation: Random Sample Observational Model: Natural History Time Perspective: Cross-Sectional Time Perspective: Retrospective Study Start Date : April 2001 Study Completion Date : September 2001 Groups and Cohorts Go to Outcome Measures Go to Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important

2003 Clinical Trials

5031. IVIG

Summary: This study will look at the safety and effectiveness of an experimental medication containing antibodies (Omr-IgG-am™) in people with West Nile Virus (WNV) who already have brain and/or spinal cord inflammation or who are at high risk of developing these problems because they have weak immune systems. WNV can cause problems such as headaches, fever, muscle weakness, coma, and death. Study investigators believe people who are not able to fight infection well may be at risk for developing (...) fluid, AND Clinical illness compatible with WNV infection as described by occurrence of greater than or equal to 3 of the following findings during the preceding less than or equal to 10 days: Diarrhea Headache Fever > 38º C Nausea and/or vomiting Myalgias and/or arthralgias Nuchal rigidity Macular or papular rash New neurological abnormality AND A risk factor for the development of WNV neurologic disease as defined by: Age greater than or equal to 40 years, or Age greater than or equal to 18 years

2003 Clinical Trials

5032. Expanded Dryvax Dilution Study in Previously Vaccinated Adults

safety endpoints include safety data regarding the three doses of vaccine in previously vaccinated subjects as assessed by adverse events reported by the subjects and/or investigators and changes observed during the scheduled clinic visits. Specific attention will be paid to the following: local reactogenicity at the site of injection: pain, tenderness, erythema, induration, regional lymphadenopathy, limitation of limb movement; systemic symptoms: fever, myalgia, fatigue, and headache; anaphylaxis (...) . Availability for follow-up for the planned duration of the study (at least 26 weeks after vaccination). Acceptable medical history by screening evaluation and brief clinical assessment. Negative urine or serum pregnancy test for women of childbearing potential. If the subject is female and of childbearing potential, she must use an acceptable contraception and not become pregnant within 56 days post vaccination. (Acceptable contraception includes implants, injectables, combined oral contraceptives

2002 Clinical Trials

5033. An Investigation of the Antidepressant Efficacy of the 5-HT2A Antagonist, M100907, in Combination With Citalopram in Treatment Resistant Depression

examination for screening Thyroid screening Collection of blood for chemistry and hematology Hepatitis B and C/HIV screening Beta-HCG pregnancy test, if applicable Urine drug screening Urinalysis Tests using the Hamilton Depression Rating Scale and the Montgomery-Asburg Depression Rating Scale Use of the Antidepressant Treatment History A sleep study will be conducted during the steady state period and again toward the end of the double blind treatment period. Each study will involve 2 consecutive nights (...) , sleep will be studied using polysomnographic methods before and after randomization. Sleep disturbance is also a well-known side effect of SSRI's, and the addition of M100907 may improve sleep disturbance related to the affective disorder itself or to iatrogenic SSRI effects on sleep. Examination of improvement in sexual side effects, gastrointestinal side effects, headache frequency, and anxiety will also be investigated in the comparison of addition of M100907 versus placebo in escitalopram

2003 Clinical Trials

5034. Omr-IgG-am(Trademark) for Treating Patients With or at High Risk for West Nile Virus Disease

. Hospitalized patients without encephalitis and/or myelitis as defined below who meet the following criteria: A positive IgM serology or PCR test for WNV in blood or cerebrospinal fluid, AND Clinical illness compatible with WNV infection as described by occurrence of greater than or equal to 3 of the following findings during the preceding less than or equal to 10 days: Diarrhea, headache, fever greater than 38 degrees Celsius, nausea and/or vomiting, myalgias and/or arthralgias, nuchal rigidity, macular (...) infectious disease, including confirmed infections with other flaviviruses) Pregnant or breastfeeding (negative serum or urine pregnancy test within previous 72 hours if woman is not postmenopausal or has not been surgically sterilized) Investigator's opinion that patient would be unable to adhere to protocol requirements Receipt of ribavirin, interferon alpha, intravenous immunoglobulin or any investigational drug for treatment of WNV or hepatitis within 15 days prior to study entry. Contacts

2003 Clinical Trials

5035. Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease

10mg/kg/day to achieve disease remission. Drug: anakinra daily injection of subcutaneous injection Other Name: Kineret Outcome Measures Go to Primary Outcome Measures : Diary Symptom Sum Score (DSSS) (Fever, Rash, Joint Pain, Vomiting, and Headaches) [ Time Frame: Baseline ] "The severity of the main symptoms of the disease were scored on a scale from 0 (no symptoms) to 4 (highest severity) on a daily basis using a diary. Five key symptoms were included in the primary variable DSSS: fever, headache (...) , rash, joint pain, and vomiting. Each of the diary variables was evaluated as a mean value for a period preceding the visits. The baseline value was the mean value of the 5-30 last days before the first dose of Kineret. For the subsequent visits, the mean value of the last 30 days with data before each visit was used as the response variable." Diary Symptom Sum Score (DSSS) (Fever, Rash, Joint Pain, Vomiting, and Headaches) [ Time Frame: 36 months ] "The severity of the main symptoms of the disease

2003 Clinical Trials

5036. Single Photon Emission Computed Tomography to Study Receptors in Parkinson's Disease

with Parkinson's disease 40 years of age and older, with or without dementia, may be eligible for this study. Candidates will be screened with physical and neurological examinations, a pen and paper test of memory and other mental functions, blood tests, and, for women of childbearing potential, a pregnancy test. Patients with cognition problems will have more intensive mental function tests. All participants will undergo the following procedures: Magnetic resonance imaging (MRI): This test uses a strong (...) , Alzheimer's disease). Use of cholinergic or anticholinergic agents within 60 days. Abnormal MRI other than mild atrophy. Claustrophobia. Pregnancy or breast feeding. Prior participation in other research protocols or clinical care in the last year such that radiation exposure would exceed the annual limits. Any conditions that increase risk for MRI (pacemaker, metallic foreign body, etc.). Any medical condition that in the opinion of the investigators would, interfere with the safe conduct of the study

2003 Clinical Trials

5037. Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma

metastases Prior radiation therapy or chemotherapy for the medulloblastoma Inadequate CSF flow on 111-Indium DTPA flow study Patients with signs or symptoms suggestive of increased intracranial pressure (headache, emesis, ocular paresis) will not be eligible until they are cleared by neurology and/or neurosurgery. Pregnancy Total bilirubin ≥ 2.0 mg/dl AST ≥ 3 x the upper limit of normal Creatinine clearance and GFR < 70 ml/min/1.73 m^2 Contacts and Locations Go to Information from the National Library

2003 Clinical Trials

5038. Clinical Trial of Estrogen for Postpartum Depression

a prophylactic effect in women at high risk for developing postpartum depression (8), suggesting that the prevention of a decline in estradiol levels (threshold or rate of decline) may prevent the onset of postpartum depression in some women; and (2) declining ovarian steroids trigger the onset of mood disturbances in women with but not women without a history of postpartum depression during a scaled down model of pregnancy in the puerperium (9). Thus, as with depressions occurring during the perimenopause (...) women porphyria diabetes mellitus cholecystitis or pancreatitis history of cerebrovascular disease (stroke), epilepsy, hypertension, hypercalcemia recurrent migraine headaches malignant melanoma history of familial hyperlipoproteinemia prior hormonal therapy for the treatment of postpartum-related mood or physical symptoms within the last six months history of psychiatric illness during the two years prior to the reported onset of the current episode of depression Contacts and Locations Go

2003 Clinical Trials

5039. Norplant and Irregular Bleeding/Spotting

Eligible for Study: 18 Years to 40 Years (Adult) Sexes Eligible for Study: Female Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria Regular menstrual periods for the last 2 cycles Currently not using hormonal contraceptives, including oral contraceptives, patch, ring, or Norplant in 2 months prior to study entry, or Depo-Provera in 12 months prior to study entry Currently not using tetracycline-class antibiotics Normal Pap smear Exclusion criteria Pregnancy or breastfeeding within 2 months (...) of study entry Chronic migraine headaches Uncontrolled high blood pressure Untreated sexually transmitted diseases Alcoholism or drug abuse within 12 months of study entry Insulin dependent diabetes Liver, kidney, or gallbladder disease Participation in another clinical trial within 30 days of study entry History of cancer History of blood clots, strokes, or heart disease Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor

2003 Clinical Trials

5040. Treatment of Pediatric Hypertension With Altace Trial

to demonstrate the efficacy and safety of ramipril in the treatment of hypertension in children ages 6 through 16 years. Condition or disease Intervention/treatment Phase Hypertension Drug: ramipril Phase 4 Detailed Description: In adults, common side effects include persistent dry mouth, dizziness, fatigue, and headache. Rare cases of angioedema have been reported. When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When (...) pregnancy is detected, ramipril should be discontinued as soon as possible. Ramipril is contraindicated in patients who are hypersensitive to the product or have a history of angioedema related to previous treatment with an ACE inhibitor. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Enrollment : 310 participants Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double Primary Purpose: Treatment Official Title: A Dose Escalation

2002 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>